The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period.

The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period.

Publication date: Mar 20, 2024

SARS-CoV-2 has acquired many mutations that influence the severity of COVID-19’s course or the risk of developing long COVID. In 2022, the dominant SARS-CoV-2 variant was Omicron. This study aimed to compare the course of COVID-19 in the periods before and during the dominance of the Omicron variant. Risk factors for developing long COVID were also assessed. This study was based on stationary visits of patients after COVID-19 and follow-up assessments after 3 months. Clinical symptoms, comorbidities, and vaccination status were evaluated in 1967 patients. Of the analyzed group, 1308 patients (66. 5%) were affected by COVID-19 in the period before the Omicron dominance. The prevalence of long COVID was significantly lower among patients of the Omicron group (47. 7% vs. 66. 9%, p < 0. 001). The risk of long COVID was higher for women (OR: 1. 61; 95% CI: 1. 31, 1. 99]) and asthmatics (OR: 1. 46; 95% CI: 1. 03, 2. 07]). Conclusively, infection during the Omicron-dominant period was linked to a lower risk of developing long COVID. Females are at higher risk of developing long COVID independent of the pandemic period. Individuals affected by COVID-19 in the Omicron-dominant period experience a shorter duration of symptoms and reduced frequency of symptoms, except for coughing, which occurs more often.

Open Access PDF

Concepts Keywords
Pandemic COVID-19
Vaccination long COVID
Women Omicron
pre-Omicron
risk factors

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Long COVID
disease VO vaccination
disease MESH infection
disease VO frequency
disease MESH Hypertension
drug DRUGBANK Coenzyme M
disease VO organization
disease MESH pneumonia
disease MESH respiratory failure
disease VO organ
disease MESH death
disease MESH syndrome
disease MESH mental disorders
drug DRUGBANK Isoxaflutole
disease MESH insomnia
disease MESH taste disorders
disease MESH chest pain
disease MESH musculoskeletal pain
disease MESH obesity
disease IDO immune response
disease MESH chronic diseases
disease IDO infectivity
disease VO time
disease VO vaccine
disease MESH emergency
disease MESH asthma
pathway KEGG Asthma
disease MESH hyperlipidemia
disease MESH heart attacks
disease MESH coronary artery disease
disease MESH thyroid diseases
disease MESH hearing impairment
drug DRUGBANK Oxygen
disease MESH hair loss
disease VO vaccinated
disease MESH coronary heart disease
disease VO USA

Original Article

(Visited 1 times, 1 visits today)